Nuvectis Pharma, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating items
Research & Development 9.54M13.23M15.38M12.92M
Wages, Salaries and Other 2.57M2.38M3.46M3.46M
Share-based Compensation (IS) 0.51M
Selling, General & Administrative 0.01M3.35M6.01M7.52M6.93M
Restructuring Costs 0.36M0.42M0.55M0.36M
Operating Expenses 0.01M13.26M19.66M23.45M20.21M
Operating Income -10.00M-12.89M-19.23M-22.90M-19.85M
EBIT -10.00M-12.89M-19.23M-22.90M-19.85M
Non-operating items
Interest & Investment Income 0.00M0.15M0.64M0.85M
Net income details
EBT -10.00M-12.89M-19.09M-22.26M-19.00M
Profit After Tax 0.01M-12.89M-19.09M-22.26M-19.00M
Income from Continuing Operations -10.00M-12.89M-19.09M-22.26M-19.00M
Consolidated Net Income -10.00M-12.89M-19.09M-22.26M-19.00M
Income towards Parent Company -10.00M-12.89M-19.09M-22.26M-19.00M
Net Income towards Common Stockholders -0.01M-12.89M-19.09M-22.26M-19.00M
Additional items
EPS (Basic) 0.00-3.02-1.51-1.43-1.11
EPS (Weighted Average and Diluted) 0.00-3.02-1.51-1.43-1.11
Shares Outstanding (Weighted Average) 11.60M11.60M14.64M17.33M19.32M
Shares Outstanding (Diluted Average) 3.90M
EBITDA -10.00M-12.89M-19.23M-22.90M-19.85M
Shares Outstanding 3.90M